What Psoriasis Is

Psoriasis is a chronic immune-mediated inflammatory disease that primarily affects the skin, nails, and joints. The most common form — plaque psoriasis vulgaris (90% of cases) — manifests as well-demarcated erythematosquamous plaques, salmon-colored with silvery-white scales, frequently on elbows, knees, scalp, and sacral region. The course is chronic-relapsing with periods of exacerbation and remission.

Global prevalence of 2–3% of the population, with no sex predilection, with two peaks of incidence: 20–30 years (type I, associated with HLA-Cw6) and 50–60 years (type II). Relevant systemic comorbidities include psoriatic arthritis (20–30% of cases), metabolic syndrome, cardiovascular disease, and depression. The psychosocial impact is marked: stigma, isolation, and impaired body identity are prevalent complaints.

Pathophysiology of Psoriasis

  1. Activated plasmacytoid dendritic cells

    Skin trauma or infection activates pDCs via self RNA → IFN-α production → activation of myeloid dendritic cells

  2. IL-23 / IL-17 axis

    IL-23 produced by myeloid DCs expands Th17 lymphocytes and ILC3; IL-17A and IL-17F are the central effectors of psoriasis — target of the most modern biologics

  3. TNF-α and IL-22 — hyperproliferation

    TNF-α amplifies inflammation; IL-22 stimulates keratinocyte hyperproliferation; epidermal turnover of 28–30 days reduces to 3–4 days

  4. Dermal angiogenesis

    Elevated VEGF; dilation and tortuosity of papillary capillaries; erythema and the characteristic "Auspitz sign" (bleeding points)

  5. Köbner phenomenon

    Skin trauma (scratch, tattoo, phlebotomy) precipitates new plaques in 25–30% of patients — mediated by keratinocyte activation by mechanical pressure

Classification and Severity Assessment

  • PASI (Psoriasis Area and Severity Index, 0–72): mild <10; moderate 10–20; severe >20 — standard in clinical trials
  • BSA (Body Surface Area): percentage of body surface affected; 1 palm = 1% BSA
  • DLQI (Dermatology Life Quality Index): assesses impact on quality of life; >10 indicates very large impact
  • Nail psoriasis: pits, onycholysis, oil spots — predictor of psoriatic arthritis
  • Psoriatic arthritis: rheumatologic assessment for DAS28, DAPSA — systemic treatment mandatory

Conventional Treatments

Treatment of psoriasis is escalated according to severity (PASI, BSA, DLQI) and the presence of psoriatic arthritis. The biologics revolution has transformed the prognosis of moderate-to-severe psoriasis over the past two decades.

THERAPEUTIC APPROACHES IN PSORIASIS

APPROACHEFFICACYLIMITATIONSCOMPATIBLE WITH ACUPUNCTURE?
Topical corticosteroids + vitamin D analogsHigh for mild-to-moderate psoriasis; clobetasol + calcipotriolAtrophy with prolonged use; tachyphylaxis; limited in extensive areasYes — acupuncture complements for control of pruritus and stress
Methotrexate / cyclosporineHigh for moderate-to-severe psoriasis; systemic immunosuppressionHepatotoxicity (MTX), nephrotoxicity (cyclosporine); laboratory monitoringYes — acupuncture as quality-of-life support and stress reduction
Anti-IL-17 biologics (secukinumab, ixekizumab)Very high; PASI 90 in 60–70% of patientsHigh cost; mucocutaneous candidiasis; upper airway infectionYes — acupuncture as adjuvant for quality of life; does NOT replace the biologic
Anti-IL-23 biologics (guselkumab, risankizumab)Very high; PASI 100 in 40–50%; long durationHigh cost; injection every 8–12 weeksYes — adjuvant for quality of life; does NOT replace the biologic
Medical acupunctureLimited evidence (tier C); in small studies PASI −4.6 in the acupuncture group vs. −1.2 control — heterogeneous dataDoes not modify the disease; does not replace topical/systemic/biologic; adjuvant role in mild-to-moderateComponent of integrative protocol; best for pruritus and quality of life

How Medical Acupuncture Works in Psoriasis

Proposed mechanisms — based on preclinical studies and small trials — suggest that acupuncture may modulate the IL-23/Th17 axis, reduce TNF-α, and influence inflammatory angiogenesis via VEGF through the neuroendocrine axis. This is a hypothesis supported by limited evidence; there is no robust demonstration of impact on the natural history of psoriasis.

IMMUNOMODULATORY EFFECTS REPORTED IN SMALL STUDIES

~−33%
SERUM IL-17A
Reduction reported in a small study (Complementary Therapies in Medicine 2017, n=56); lacks large-scale replication
~−28%
SERUM TNF-Α
Drop in circulating TNF-α reported after a 10-week series in the same study
~−4.6 pts
PASI SCORE
Reduction in the Psoriasis Area and Severity Index (0–72) vs. ~−1.2 in the control — small study
~−26%
CUTANEOUS VEGF
Reduction of VEGF in pilot study — suggestive mechanism, not confirmatory

Clinical Studies

The available trials on acupuncture in psoriasis demonstrate benefits especially in mild-to-moderate psoriasis and in combination with conventional topical treatments.

CLINICAL OUTCOMES — COMPLEMENTARY THERAPIES IN MEDICINE 2017 (N=56, 10 WEEKS)

~−4.6 pts
PASI SCORE
Reduction in the psoriasis severity index (acupuncture group vs. ~−1.2 control) in a small study
~−33%
SERUM IL-17A
Drop in the Th17 cytokine reported in the same study — limited sample
~−28%
TNF-Α
Reduction in circulating TNF-α reported; not replicated at large scale
~52%
CLINICAL RESPONSE
vs. ~29% in the control — defined as improvement ≥2 pts on PASI (single study)

What the Studies Suggest

  • Small studies suggest that acupuncture + standard care may surpass standard care alone for PASI and quality of life in mild-to-moderate psoriasis — replication needed
  • Reported reduction in IL-17A and TNF-α suggests a possible immunomodulatory mechanism; preliminary mechanistic evidence
  • Better signal in mild-to-moderate psoriasis (PASI <20); severe psoriasis requires biologic — acupuncture does NOT replace it
  • Psoriatic pruritus appears to respond to acupuncture — reported reduction of around 38% in a small trial
  • Köbner phenomenon: needle only intact skin; never needle over active plaques

Modern Approach: Integrative Acupuncture in Psoriasis

Medical acupuncture integrates into the psoriasis protocol in specific layers: control of stress (recognized trigger), adjuvant immune modulation, and management of psoriatic arthritis when present.

Integrative Protocol for Psoriasis

  1. Mild psoriasis (PASI <10)

    Acupuncture as primary component with topical treatment (corticosteroid + vitamin D analog); 1–2×/week for 10–12 weeks; focus on stress and pruritus control

  2. Moderate psoriasis (PASI 10–20)

    Acupuncture as adjuvant to systemic treatment (MTX or cyclosporine); 1×/week; quality-of-life support. Do NOT reduce systemic doses without the dermatologist

  3. Severe psoriasis + biologic (PASI >20)

    Acupuncture as well-being and quality-of-life support during biologic treatment; does not replace nor justify discontinuation of the biologic; dermatologic follow-up maintained

  4. Associated psoriatic arthritis

    Acupuncture for peripheral joint pain (hands, feet, knees) as a complement to rheumatologic treatment; anti-TNF or anti-IL-17 if indicated by the rheumatologist

When to See a Medical Acupuncturist

Mild-to-moderate psoriasis with a stress component as a trigger and/or significant pruritus is the most favorable indication for medical acupuncture.

Profiles With Best Response to Acupuncture

  • Mild-to-moderate psoriasis (PASI <20) with stress identified as a trigger of flares
  • Psoriasis with significant pruritus as the main complaint (NRS ≥5)
  • Psoriasis in partial remission with topical treatment — acupuncture to consolidate and prolong remission
  • Mild psoriatic arthritis with peripheral joint pain in patient with contraindication to NSAIDs
  • Psoriasis with impact on quality of life (DLQI >5) and associated anxiety or depression

Frequently Asked Questions

FREQUENTLY ASKED QUESTIONS · 05

Frequently Asked Questions

In mild psoriasis, some plaques may regress significantly or disappear with combined acupuncture + topical treatment. In moderate-to-severe psoriasis, acupuncture contributes to PASI reduction but rarely leads to skin clearance on its own — that result is more often achieved with biologics. The realistic focus of acupuncture is to reduce severity, pruritus, and frequency of exacerbations.

This is the Köbner phenomenon — and yes, this risk exists if the needle is inserted into skin with active microinflammation or close to plaques. For this reason, the medical acupuncturist must select points in intact skin, away from plaques, and use ultrafine needles (0.20–0.25 mm). The risk is minimized but not zero — it should be discussed with the patient before starting treatment.

Improvement in pruritus and general well-being usually occurs between the 3rd and 6th session. Visible reduction of plaques (PASI) is slower — expected between 8–12 weeks of treatment. An initial cycle of 10–12 sessions (2 per week in the first 4 weeks, then weekly) is the standard protocol, followed by monthly maintenance.

Yes — scalp psoriasis can be addressed with systemic acupuncture (SP-10, LI-11, ST-36) and local points on intact scalp (GV-20, BL-7). Insertion is performed in skin without active scales. Specific topical treatment for the scalp (coal-tar shampoo or corticosteroid lotion) is maintained in parallel by the dermatologist.

During a severe acute flare with extensive erythematous plaques, the priority is dermatologic treatment (short systemic corticosteroid, biologic, or hospitalization in severe cases). Acupuncture can be performed at distal points (hands, feet) without risk, but its role is greater in the maintenance phase and prevention of relapses than in the control of the acute flare.

Related Articles

Acupuncture for Atopic DermatitisAcupuncture for Chronic UrticariaAcupuncture for Alopecia AreataAcupuncture for Rheumatoid Arthritis